Log in with your email address username.


[Comment] New pathways of treatment for psoriatic arthritis

Psoriatic arthritis occurs in up to 30% of patients with psoriasis.1 The prevalence of psoriasis varies geographically, ranging between 1% and 3% of the population, depending on genetic variation.2 Since the discovery of the cytokine interleukin 17A in 1993, and the subsequent discovery of one of the key cells that produce interleukin 17A and related cytokines, the T-helper-17 cell, in 2005,3 this pathway has been a focus of research in the pathogenesis of psoriasis and closely related conditions, psoriatic arthritis and spondyloarthritis.